2017
June

GMA301 was selected as “National Mega-Innovative Program”

June, 2017, GMA301 was selected as the “National Mega-Innovative Program” for the 13th Five Year Plan. This designation is granted by the ...

2017
February 6

GMA102 IND registration accepted by CDE

February 6, 2017, CDE has accepted the IND registration of GMA 102.
GMA102 is a humanized antibody against GLP-1R for type 2 diabetes and ...

 

2016
April 29

GMA102 started phase 1 clinical trial in Australia

April 28, 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia...

 

2015
October 29

CDE accepted GMA204 IND registration and started on-site inspection

April 28, 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia...

 

2014
December

Gmax Biopharm closes the A round financing

December 2014, Gmax Biopharm closes the A round financing with 43 million RMB. The raised capital is mainly for moving forward the pipeline... products to clinical trials.

 


5 Records